会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • METHOD OF PRODUCING ANTIBODIES WITH CONJUGATES OF B-CELL-ANTIGEN AND DENATURED CARRIER
    • 生产具有B细胞抗原和被去除载体的抗体的方法
    • WO1994012213A1
    • 1994-06-09
    • PCT/DK1993000382
    • 1993-11-24
    • BUCHARDT, OleKOCH, ClausNIELSEN, Peter, Eigil
    • A61K39/395
    • A61K39/385A61K2039/6081
    • Antibodies to haptens and other B cell antigens are provided in animals by a process wherein the B cell antigen is introduced into the animal in a form in which it is coupled to an immunogenic carrier molecule in the form of a protein antigen which normally induces both T cell and B cell immunity. The process is unique in that the immunogenic protein antigen is modified to an exclusive or predominant T cell antigen by a denaturating modification of the antigen, that the B cell antigen to which antibodies are to be provided is coupled to the modified T cell antigen, followed by immunization, optionally using an adjuvant as an immune stimulating means, preferably after preimmunization with T cell antigen in a form that may be different from the form used in the immunization proper with the B cell antigen. The produced antigens are particularly used in the production of vaccines for veterinary medicinal use.
    • 通过以下方法提供动物中的半抗原和其他B细胞抗原的抗体,其中将B细胞抗原以与蛋白质抗原形式的免疫原性载体分子偶联的形式引入动物,通常诱导T 细胞和B细胞免疫。 该过程是独特的,因为通过抗原的变性修饰将免疫原性蛋白抗原修饰为排他或主要的T细胞抗原,将要提供抗体的B细胞抗原与修饰的T细胞抗原偶联,随后 通过免疫,任选地使用佐剂作为免疫刺激手段,优选在以与B细胞抗原适当的免疫中使用的形式不同的形式的T细胞抗原预先免疫后。 产生的抗原特别用于生产用于兽医用途的疫苗。
    • 5. 发明申请
    • A METHOD OF DETERMINING THE PRESENCE OF ENDOTOXIN IN A SAMPLE
    • 确定样品中内毒素存在的方法
    • WO1988009507A1
    • 1988-12-01
    • PCT/DK1988000081
    • 1988-05-19
    • BAEK, LeifKOCH, Claus
    • G01N33/579
    • G01N33/579G01N33/56916
    • In a method of determining the presence of an endotoxin or endotoxin-like material in a sample, a) a sample is incubated with a component of horseshoe crab amoebocytes lysate or haemolymph or a synthetic analogue thereof, b) the incubated mixture of the sample and the component or analogue resulting from step a) is reacted with an antibody raised against the component or analogue or against a reaction product of the incubation of step a), and c) the presence of endotoxin or endotoxin-like material in the sample is determined by detecting any bound antibody in the reaction mixture of step b). In the method either the component or analogue or the antibody or the endotoxin or endotoxin-like material is coupled to a solid support.
    • 在测定样品中存在内毒素或内毒素样物质的方法中,a)将样品与马蹄蟹变形细胞裂解物或血淋巴或其合成类似物的组分一起温育,b)将样品和 由步骤a)得到的组分或类似物与针对组分或类似物产生的抗体或与步骤a)的培养反应产物反应,和c)测定样品中内毒素或内毒素样物质的存在 通过检测步骤b)的反应混合物中的任何结合的抗体。 在该方法中,组分或类似物或抗体或内毒素或内毒素样物质偶联至固体支持物。
    • 6. 发明申请
    • METHOD OF DETERMINING FUNCTIONAL DEFICIENCIES IN THE COMPLEMENT SYSTEM
    • 确定补充系统中功能缺陷的方法
    • WO2009030240A2
    • 2009-03-12
    • PCT/DK2008050221
    • 2008-09-05
    • IMMUNOBOND APSPALARASAH YASEELANOLE SKJOEDT MIKKELVITVED LARSKOCH CLAUS
    • PALARASAH YASEELANOLE SKJOEDT MIKKELVITVED LARSKOCH CLAUS
    • G01N33/564
    • G01N33/564
    • The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier. The second kit comprises a container comprising a predetermined amount of one or more inhibitors of the classical and the alternative complement pathways and a diluent, wherein the container is adapted for receiving a predetermined amount of sample, so that when the predetermined amount of sample is added, the concentration of the one or more inhibitors is an inhibitory effective concentration of the classical and alternative pathways, but not the lectin pathway.
    • 本发明涉及体外确定补体系统的凝集素途径中功能缺陷的方法,所述方法包括以下步骤:(a)用稀释剂稀释哺乳动物体液样品,所述稀释剂包含一种或多种 补体系统的经典和替代途径; (b)激活从(a)获得的样品中补体系统的凝集素途径; 和(c)确定从(b)获得的样品中一种或多种补体因子C3,C4或C5-C9复合物的一种或多种组分的活化。 本发明还涉及与上述方法结合使用的试剂盒,第一试剂盒包含:i)第一组分,其包含载体,一种或多种经典和可选补体途径的抑制剂以及稀释剂; 和ii)第二组分,其包含一种或多种用于激活凝集素补体途径的物质和任选的惰性载体。 第二试剂盒包含容器,该容器包含预定量的一种或多种经典补体途径和替代补体途径的一种或多种抑制剂和稀释剂,其中该容器适于接收预定量的样品,从而当添加预定量的样品 ,一种或多种抑制剂的浓度是经典途径和替代途径的抑制性有效浓度,但不是凝集素途径。